Navigation Links
Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
Date:6/28/2010

CAMBRIDGE, Mass., June 28 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.

"For decades, our primary treatment option for patients with type 1 diabetes has been the use of insulin alone to control blood glucose levels, while the underlying autoimmune disease continues to progress," said Dr. Thomas B. Repas, Clinical Assistant Professor, Department of Internal Medicine, University of South Dakota, Sanford School of Medicine, and an investigator in the DEFEND-2 study.  "The future potential of otelixizumab opens up the opportunity for an entirely new treatment approach that can intervene at early onset of type 1 diabetes and potentially break the cycle of the continued progression of this disease that patients manage over their entire lifetime."

DEFEND-2 is a randomized, placebo-controlled confirmatory Phase 3 trial designed to enroll up to 400 patients, age 12 to 45, with newly diagnosed autoimmune type 1 diabetes. DEFEND-2 is being conducted at more than 200 sites in North America and Europe. Building on DEFEND-1, the DEFEND-2 clinical trial similarly evaluates the efficacy and safety of otelixizumab in an additional study population of patients
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
7. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
8. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... (NYSE: DHR ) announced today that Henk ... and Amir Aghdaei and Henrik Roos have each been ... In his new role, Henk van Duijnhoven will ... Group and Sybron Dental Specialties.  Danaher,s Dental segment generated ...
... ALISO VIEJO, Calif., April 5, 2011 Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the Future Leaders ... Location: Millennium Broadway Hotel & Conference Center, New York, ... Presentation time: 2:00pm ET A live ...
Cached Medicine Technology:Danaher Announces Executive Appointments 2
(Date:4/22/2014)... patients diagnosed with non-small cell lung cancer are 70 ... percentage, these elderly patients are not well represented in ... made it difficult to reach evidence based clinical recommendations. ... Task Force and Lung Cancer Group along with the ... opinion on managing treatment for elderly patients with non-small ...
(Date:4/22/2014)... trauma, illness, alcohol or other drug abuse, these stressors ... that can go awry and activate conditions such as ... , Until now, it has been unclear how much ... brain. Past studies have shown that when an expectant ... she experiences some trauma or illness, her baby may ...
(Date:4/22/2014)... intervention researchers have been informed that the National Institute ... Institutes of Health, will award an $8 million grant ... an experimental drug for stroke. , The drug, ... plasminogen activator, or rtPA the "clot-busting" drug currently ... laboratory rodent studies, 3K3A-APC, used in combination with rtPA, ...
(Date:4/22/2014)... a clinical trial led by Dana-Farber Cancer Institute ... approved a molecularly targeted drug as second-line treatment ... standard chemotherapy has failed. , The FDA approval ... manufacturer, Lilly Oncology, of Indianapolis. A monoclonal antibody ... sold under the name Cyramza, and is the ...
(Date:4/22/2014)... the University of Calgary,s Hotchkiss Brain Institute (HBI) uncovers ... as a means to restore connections after injury. Dr. ... molecule that directly regulates nerve cell growth in the ... prestigious journal Nature Communications , with lead authors ... made the surprising discovery that a protein called Retinoblastoma ...
Breaking Medicine News(10 mins):Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Scientists discover a new way to enhance nerve growth following injury 2
... , ... ... ... ...
... ... ... ... ...
... sheds light on brain mechanism related to processing images , ... recognizing faces may be relieved to know that the problem ... could be in their genes, new research suggests. , The ... genes) and 125 non-identical, same-sex twins (who share 50 percent ...
... C. Bray of the University of Calgary was recently ... for Sports Medicine,s (AOSSM) $250,000 Ligament and Tendon Repair ... Ligament and Tendon Healing: Role of Neuropeptides." ... of Calgary, and Per Renstrom and Paul Ackermann, both ...
... mechanisms of transport have important applicationstransport of nutrients ... aeration of agricultural soils, performance of chemical reactors, ... and the design of clay membranes for retaining ... has important roles in biology, physics, and chemistry, ...
... ... depression and stress with amazing technology; free assessments offered in March. , ... Arlington, TX (Vocus) February 24, 2010 -- The ... trigger anxiety, loneliness, depression and even thoughts of suicide. At New Life Brain Center™, ...
Cached Medicine News:Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 2Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 3Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 4Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 5Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 6Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 7Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 8Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 9Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 10Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 11Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 12Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 13Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 14Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 15Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 16Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 17Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 18Health News:Soyfoods Aid Those With Lactose Intolerance 2Health News:Soyfoods Aid Those With Lactose Intolerance 3Health News:Soyfoods Aid Those With Lactose Intolerance 4Health News:Soyfoods Aid Those With Lactose Intolerance 5Health News:Trouble Recognizing Faces Could Be Genetic 2Health News:$250,000 grant awarded for groundbreaking ligament and tendon repair research 2Health News:Where does the fluid go? 2Health News:Brain Balancing Gives Hope for Sufferers of Depression, Stress, and Insomnia at New Life Brain Center, 2Health News:Brain Balancing Gives Hope for Sufferers of Depression, Stress, and Insomnia at New Life Brain Center, 3
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
BD Vacutainer® Specialty Tubes - Acid Citrate Dextrose (ACD)...
... BD Vacutainer® SST™ Tubes ... a polymer gel for ... used for serum determinations ... provide an efficient means ...
MONOJECT Red/Yellow Mottled Stopper...
Medicine Products: